Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN65030013
ISRCTN65030013
Active, not recruiting
未知

Therapy Personalisation using Multiomic Analyses in Inflammatory Bowel Disease – THAMES-IBD

Imperial College London0 sites468 target enrollmentJune 23, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsInflammatory Bowel DiseaseDigestive SystemCrohn’s disease, ulcerative colitis

Overview

Phase
未知
Intervention
Not specified
Conditions
Inflammatory Bowel Disease
Sponsor
Imperial College London
Enrollment
468
Status
Active, not recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 23, 2022
End Date
December 1, 2027
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Healthy control patients:
  • •1\.1\. \=18 years\-old
  • •1\.2\. Willing to consent to sample collection
  • •1\.3\. No prior diagnosis or current clinical suspicion of IBD
  • •2\. Inflammatory bowel disease patients, including ulcerative colitis, Crohn’s disease and IBD\-unclassified
  • •2\.1\. Active disease as determined by standard clinical parameters measured within the 2 months prior to recruitment:
  • •\- Crohn's symptom flare as indicated by Harvey\-Bradshaw score \>5 or unweighted PRO\-2 (CD) of average daily stool stool frequency (SF) score \=4 and/or average daily abdominal pain (AP) score \=2,
  • •\- faecal calprotectin \=250micrograms/gram;
  • •\- UC / IBD\-U symptom flare as indicated by PRO\-2 (UC) of \=3 including a rectal bleeding score of \=1,
  • •\- faecal calprotectin \=250micrograms/gram.

Exclusion Criteria

  • •Unable or unwilling to provide informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Study for personalized medicine based on pharmacokinetics and pharmacodynamics concerned with therapeutic drug of nontuberculous mycobacterium.
JPRN-UMIN000020406Center for Infectious Disease and Infection Control10
Recruiting
Not Applicable
Deep-phenotyping and personalized therapy of patients with irritable bowel syndromeF45.32K58Irritable bowel syndrome
DRKS00032767niversitätsklinikum Heidelberg, Abteilung für Allgemeine Innere Medizin und Psychosomatik75
Not yet recruiting
Phase 4
Treatment of neovascular AMD: Artificial intelligence in real-world setting
2024-518482-99-01Medical University Of Vienna290
Completed
Not Applicable
Biomarker testing for Personalized Therapy in real world setting; First line treatment decision in the advanced non-squamous NSCLCnon-squamous Non-small-cell lung carcinoma
JPRN-UMIN000030618AstraZeneca K.K.200
Recruiting
Not Applicable
Genetic Biomarker Research for Personalized Therapy of Chorioretinal Neovascular DiseasesDiseases of the eye and adnexa
KCT0001055Inje University Busan Paik Hospital1,000